Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis
Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
Age is a risk factor for graft-versus-host disease (GVHD) after human leukocyte antigen
(HLA)-matched sibling allogeneic stem cell transplantation (allo-SCT). The incidence of acute
GVHD is significantly higher in patients at 40 years of age or more than those at 18 to 39
years of age after allo-SCT. It was found that Anti-thymocyte globulins can be used for
prophylaxis of both acute and chronic GVHD after allo-SCT.Prophylaxis of GVHD using ATG in
patients at 40 years of age or more in matched sibling allo-SCT settings might significantly
decrease the incidence of acute and chronic GVHD and the incidence of late effect after
transplantation.